Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST® (rilonacept) Q3 2022 net revenue of $33.4 million –– RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p